ID | 32200 |
JaLCDOI | |
FullText URL | |
Author |
Ohnoshi, Taisuke
Hiraki, Shunkichi
Ueda, Nobuo
Fujii, Masafumi
Machida, Ken-ichi
Ueoka, Hiroshi
Kawahara, Shin
Kozuka, Akira
Moritaka, Tomonori
Kodani, Tsuyoshi
Kamei, Haruhito
Kimura, Ikuro
|
Abstract | Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials. |
Keywords | non-small cell lung cancer
ifosfamide
cisplatin
vindesine
|
Amo Type | Article
|
Publication Title |
Acta Medica Okayama
|
Published Date | 1991-10
|
Volume | volume45
|
Issue | issue5
|
Publisher | Okayama University Medical School
|
Start Page | 357
|
End Page | 361
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT |